Fig. 4
From: Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq
a UMAP embedding of scRNA-seq profiles from slice cultures of six patients generated using the cell score matrix from joint scHPF analysis of the entire data set colored by patient. b Same as a but colored by treatment condition. c Same as a but colored by the scHPF-imputed log-ratio of Chr. 7 to Chr. 10 average expression where a high ratio (red) indicates malignant transformation. d Same as a but colored by expression of the oligodendrocyte marker PLP1. e Same as a but colored by expression of the myeloid marker CD14. f Same as a but colored by the total expression of the T cell receptor constant regions (TRAC, TRBC1, TRBC2). g Heatmap showing the log-ratio of the average expression of the top 100 genes in each eptoposide-treated to each control slice for each scHPF factor and each of three cell types—transformed (tumor), oligodendrocyte (oligo), and myeloid. h Same as g for panobinostat-treated slices. i Violin plots showing the distributions of the average expression of the top 100 genes in the Proliferation scHPF factor for each vehicle- and etoposide-treated slice for each patient in tumor cells. All within-patient, vehicle-treatment comparisons have p<0.05 (Mann-Whitney U-test) unless otherwise indicated (N.S. or not significant). j Same as i for the Panobinostat1/MT scHPF factor for each vehicle- and panobinostat-treated slice in tumor cells. k Same as j for the Panobinostat2/Chemokine scHPF factor in tumor cells. l Same as j for the Panobinostat3/Oligo scHPF factor in oligodendrocytes. m Same as j for the Myeloid2/Pro-Inflammatory scHPF factor in myeloid cells. n Same as j for the Myeloid3/CD163 scHPF factor in myeloid cells